Neuron23(TM) Closes $113.5 Million Series A and B Financing led by Westlake Village BioPartners, Kleiner Perkins, and Redmile Group
Biotechnology company launches to accelerate development of precision medicines for genetically defined neurological and immunological diseases
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2020 -- (Healthcare Sales & Marketing Network) -- Neuron23 Inc., an e... Biopharmaceuticals, Neurology, Venture Capital Neuron23, precision medicine
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Allergy & Immunology | Biotechnology | Brain | Genetics | Marketing | Neurology | Pharmaceuticals | Venture Capital